Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldesleukin
- Development stage
- Approved
- Lead developer
- Iovance Biotherapeutics
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Aldesleukin is a recombinant analog of human interleukin-2 (IL-2), a cytokine that plays a central role in the activation and proliferation of lymphocytes. It is produced by recombinant DNA technology using genetically engineered Escherichia coli containing an analog of the human IL-2 gene[9]. Aldesleukin binds to the interleukin-2 receptor on immune cells, leading to activation and proliferation of T cells and natural killer (NK) cells. This results in enhanced immune-mediated cytotoxicity against tumor cells[5][4]. Aldesleukin is primarily indicated for metastatic renal cell carcinoma and metastatic melanoma[1][7]. Its use can cause severe side effects including capillary leak syndrome, hypotension, organ dysfunction, and neurotoxicity; therefore it must be administered under close medical supervision in hospital settings[1][8].
- Brand names
- Proleukin
- Other names
- interleukin-2interleukin2interleukin 2recombinant interleukin-2IL-2IL2IL 2
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)IL2RB (IL-2 receptor beta chain)IL2RG (Interleukin-2 receptor gamma subunit)
Beyond the preview
Go deeper on aldesleukin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldesleukin.